TARGETED ANTIBODY THERAPY

WHAT IS TARGETED ANTIBODY THERAPY?

Targeted antibody therapy is a form of immunotherapy that uses antibody-based drugs to bind specifically to certain proteins on targeted cells, with the aim of modulating the patient’s immune system to attack and kill the cancer cells without harming normal cells.

Immunoglobulin G (IgG) monoclonal antibodies (mAbs) are the predominant molecular format used in currently approved antibody drugs, with over 30 mAbs approved by the USFDA for various oncology indications.

Other antibody formats becoming increasingly common in oncology drug development include antibody drug conjugates, which are antibodies armed with toxins, and bispecific antibodies that recruit T cells or other immune cells to kill tumour cells.

Biosceptre is currently developing human-derived antibody therapeutics that target nfP2X7 for use in both solid and haematological tumours.

BACK TO INNOVATION